View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
June 8, 2021

Coronavirus company news summary – Thermo Fisher launches assay for Covid-19 surveillance – FDA grants EUA to OraSure’s Covid-19 rapid antigen tests

By Chloe Kent

Thermo Fisher Scientific has launched the Ion AmpliSeq SARS-CoV-2 Insight Research Assay. The assay is designed to help identify new and known Covid-19 variants from samples with lower viral loads. It sequences more than 99% of the SARS-CoV-2 genome, covering all potential serotypes. The assay enables workflow automation and reduces the turn-around time for insights and data.

Biotechnology company Avacta Group announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA), has registered its AffiDX SARS-CoV-2 antigen lateral flow test. Clinical data for the antigen lateral flow test showed 100% sensitivity in identifying infectious individuals with viral loads measured by PCR of Ct<27.

OraSure Technologies has announced that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the company’s Covid-19 rapid antigen tests, the InteliSwab. The InteliSwab Covid-19 Rapid Test is now available for over-the-counter (OTC) non-prescription use, the InteliSwab Covid-19 Rapid Test Pro is available for professional use and the InteliSwab Covid-19 Rapid Test Rx is available for home use.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network